Here is the design of a clinical trial:

Official Title: A Phase II Study of PD-1 Antibody Plus Neoadjuvant Chemotherapy for Advanced-stage Ovarian Cancer (Z2HOC-01)

Included conditions:
- Ovarian Cancer
- Neoadjuvant Chemotherapy
- Anti-PD-1
- Neoadjuvant Immunotherapy

Study Armgroups:
- {'label': 'NIC', 'type': 'EXPERIMENTAL', 'description': '1. Neoadjuvant treatment BGB-A317 200mg q3 weeks (total 3 dosing) Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)\n2. Interval debulking surgery and HIPEC\n3. Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)', 'interventionNames': ['Drug: BGB-A317', 'Drug: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5']}
- {'label': 'NC', 'type': 'ACTIVE_COMPARATOR', 'description': '1. Neoadjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)\n2. Interval debulking surgery and HIPEC\n3. Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)', 'interventionNames': ['Drug: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5']}

Interventions:
- {'type': 'DRUG', 'name': 'BGB-A317', 'description': 'PD-1 antibody，Tislelizumab (BGB-A317)', 'armGroupLabels': ['NIC']}
- {'type': 'DRUG', 'name': 'albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5', 'description': 'albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5', 'armGroupLabels': ['NC', 'NIC']}

Primary Outcomes:
- {'measure': 'Progression-free survival(PFS)', 'description': '12 months progression-free survival rate will be estimated, and 95% confidence intervals will be calculated.', 'timeFrame': '12 months'}

Please estimate the sample size based on the assumption: 
One-sided significance level of α=0.05, 80% power, and a dropout rate of 10%.
Sample size and randomisation
        This is an exploratory biomarker study, and any statistical comparisons between the two treatment arms will be exploratory in nature. Moreover, the study is structured as a parallel-group randomised trial, with the primary outcome being the 1-year PFS rate. The randomisation ratio is 1:1. Assuming a 1-year PFS rate of 60% in the control group14 15 and 80% rate (a 20% increase) in the treatment group, with a one-sided significance level of Î±=0.05 and 80% power, the study requires a sample size of 40 subjects (20 in each group), a dropout rate of 10% is assumed. The requisite sample size was calculated using PASS 15. Randomisation will be performed using a computer-generated programme that incorporates a random element, which will ensure a balance of the tumour stage.